



Where Technology Comes To **Life**

Company presentation





Forward Looking Statement

This presentation contains forward-looking statements within the Israeli Securities Law, 1968, the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws, as amended, regarding Pluri Inc. and/or its subsidiaries (collectively the "Company" or "Pluri"), to the extent such statements do not relate to historical or current facts. For example, the Company is using forward-looking statements when it discusses the potential benefits of its solutions and the solutions of its subsidiaries and joint venture; its ability to create a collaborative network of ventures and partnerships; the ability of its technological platform; its ability to retain majority share ownership in every venture it creates; its ability to grow stronger and drive continuous innovation and success; and potential market size and growth for its solutions. Forward-looking statements are based on management's current expectations, estimates, projections, and assumptions about future events, and are subject to several factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions about the Company, which are difficult to predict, including projections of the Company's future financial results, its anticipated growth strategies, and anticipated trends in its business and in the market generally.

Therefore, actual future results, performance and trends may differ materially from these forward-looking statements due to a variety of factors, including, without limitation: changes in technology and market requirements; delays or obstacles in launching plans, including R&D; products may not be approved by regulatory agencies; technology may not be validated; methods may not be accepted; inability to retain or attract key employees; unforeseen scientific difficulties; products may be more expensive than anticipated; laboratory results may not translate to real world; patents may be insufficient; products may harm recipients; adverse legislation; loss of market share and pricing pressure from competition. The factors listed are not exclusive; further information is contained in the Company's Annual Report on Form 10-K and other reports on file with the U.S. Securities and Exchange Commission.

This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities of the Company. The information presented is not intended to replace the need to review the Company's formal filings with the U.S Securities and Exchange Commission, including its Annual Report on Form 10-K and any subsequent filings, prior to making any investment. In case of any inconsistencies between this presentation and the Company's regulatory filings, the latter will prevail. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements. More detailed information about risks and uncertainties is contained under "Risk Factors" in the Company's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC and available on www.sec.gov.

Longevity - a Macroeconomic Necessity



The World Health Organization (WHO) reinforces healthy ageing as a systems-level priority. Nations facing demographic cliffs make investment a political and economic mandate.

About Pluri

Cell-based innovation - across modalities



20+

Years of cell-processing
experience

200+

Global patents

~\$10m

Cash & Deposits
(as of March 31, 2026)

GMP

In-house commercial-scale
facility

Discovery-Phase III

CMC approved
by key regulators

Leadership

Seasoned leadership
Chairman - Alejandro Weinstein

Pluri's Unique Platform

Next-generation cell-based solutions at scale - across two billion-dollar verticals

ONE PLATFORM. TWO VERTICALS. INFINITE OPPORTUNITIES.

HUMAN HEALTH & LONGEVITY

Cell therapies + regenerative aesthetics

- Allogeneic, Off-the-Shelf, ready to use products.
- From discovery to Phase III- CMC approved by key regulators.
- PLX placental cell therapy- robust clinical evidence, >1000 patients in clinical studies.
- **cella** exosome line - regenerative aesthetics
- Commercial milestones in 2026

Core Operational Programs

FOODTECH & BIO-FARMING

Plant + animal cells at industrial scale

- Pluri contributes its technology to each venture in exchange for majority ownership, scaling value across multiple verticals:
- **coffeesai** - cultivated coffee 100% ownership
- **kokomodo** - cultivated cacao 79% ownership
- **ever after** - cultivated meat, 69% ownership (value of \$62 million)
- Multi-projects in cell-based agriculture

Platform Ventures
(Significant equity, Non-operational)



TECHNOLOGY

Our 3D Bioreactor Platform

A proprietary system that expands any cell type - human, plant and animal into industrial-scale volumes with full reproducibility.

Reproducible

Closed-system process, batch-to-batch consistency.

GMP-Certified

Manufacturing recognized by key regulators.

Scalable

From lab-scale to commercial in a single platform.

One platform. Any cell. Industrial scale.

**Platform for commercial opportunities:
Core technology platform allowing versified pipeline
across different industries.**



Human Health & Longevity

Advancing longevity and
regenerative medicine at the cellular level



The Rise of Longevity Investment Capital

Longevity is no longer just a market - it's a new axis of power

SOVEREIGN WEALTH FUNDS

Longevity investment as national strategy

\$11.2T

International Forum of Sovereign Wealth Funds (IFSWF) AUM

\$1.06T

Abu Dhabi Investment Authority AUM

\$557B

Qatar Investment Authority AUM

FAMILY OFFICES & ULTRAWEALTHY

The most important class of longevity backer

220%

Increase in global investment in longevity companies from 2023 to 2024

\$3B

Bezos & Milner - Altos Labs (cellular rejuvenation)

\$1B

Sam Altman - Retro Biosciences Series A


\$435M

Brian Armstrong - NewLimit Series C (epigenetic reprogramming)

Source: Forbes - "The Longevity Coup" (2025); Goldman Sachs survey (2023)

Longevity - the Human Impact

Aging is a multi-system decline. Pluri's regenerative cell platform targets its root cause.



1 Neurodegenerative

Alzheimer's, Parkinson's, cognitive decline

2 Cardiovascular

Heart failure, vascular insufficiency

3 Hematopoietic Decline

Bone marrow failure, immunosenescence

4 Musculoskeletal

Sarcopenia, osteoarthritis, frailty

5 Chronic Inflammation

Inflammaging & immune dysregulation

6 Oncogenic Processes

Age-related malignancies

The hallmark biology underlying multi-system decline

Pluri's platform directly targets senescent-cell burden and tissue regeneration - addressing the upstream driver of every condition above.

PLX Cell Therapy Platform: Human Health & Longevity

Allogeneic, placental-based, off-the-shelf therapy with multi-indication clinical track record

~1,000 patients participated in clinical trials globally · **20,000+** treatments per single placenta



Vascular & Wound Healing

Critical Limb Ischemia (CLI)

Reduction in amputations & mortality vs placebo

Phase III - U.S., EU, Israel (N=213)



€7.6M EU Horizon 2020 grant funding



Muscle & Tissue Regeneration

Total Hip Arthroplasty

improvement in muscle strength & volume vs placebo

Phase III - Global (N=240)



€7.4M EU Horizon 2020 grant funding



Pain Management & OA

Knee Osteoarthritis (OA)

Aiming to reduce inflammation and cartilage degeneration

Phase I ongoing - Charité Berlin



€7.5M EU Horizon grant funding



Bone Marrow Regeneration

Poor Graft Function (PGF)

Reduction in mortality & blood transfusion products

Phase I - U.S. (N=21)

Acute Radiation Syndrome (ARS)

Increased survival rates vs placebo

FDA Animal pathway



Regenerative Aesthetics Through Cell Science

Transforming decades of cell-science expertise into next-generation commercial aesthetics




MARKET OPPORTUNITY

>\$200B

Global aesthetics & wellness industry

Driven by demand for evidence-based, biotech-powered, and clean solutions.

Launching in 3 Markets during 2026



SCIENCE-DRIVEN INNOVATION

Plant EVs · Placental Exosomes

Rich in exosomes, cytokines and growth factors.
Designed to rejuvenate, repair, and elevate skin vitality.

CLINICALLY VALIDATED

Significant improvements in skin elasticity, firmness, skin-fatigue, vascular tone (redness) & brown discoloration.

COMMERCIAL LAUNCH 2026 – U.S. MARKET

Completed product listing of two regenerative aesthetic products in the U.S.;
Cellav is expected to reach the U.S. market during 2026, entering a rapidly expanding U.S. medical aesthetics market, projected to reach \$90 billion by 2030.



OUR VISION

Cells are the Building Blocks of **Life**.



Aging and Health



Climate Change



Food Security



Sustainability

Our technologies enables scalable, sustainable solutions for a growing, **aging world**.

**Eight Billion Lives.
One Planet.
Zero Time to Waste.**

Innovating the Future of Food & Bio-Farming

Pluri contributes its technology to each venture in exchange for majority ownership, scaling value across multiple verticals



ever after **Cultivated Meat**
FOODS

69% Pluri Ownership
Current valuation \$62M

Bühler partnership + Tnuva strategic investment



kokomodo **Cultivated Cacao**

79%
Strategic JV

In partnership with Plantae Bioscience & Strauss Group



coffeesai **Cultivated Coffee**

100%
Wholly-owned by Pluri

Real coffee from plant-cell cultivation



Bio-Farming

Multiple disruptive projects in alternative seed production, biostimulates, etc.

Value driven events to pluri through multiple global collaborations and strategic investments

2026 - Inflection Point

Key catalysts converging across both verticals this year

LONGEVITY & HEALTH

- Cellav regulatory approvals across U.S. & EU & IL.
- Commercial launch of Cellav regenerative aesthetics products - multiple distribution and collaboration agreements.

FODDTECH & BIO-FARMING

- Ever After Foods: bioreactor launch with partner.
- Coffeesai & Kokomodo: initial regulatory filings U.S. & IL.
- Value driven events to pluri through multiple global collaborations and strategic investments.

2026

WHY 2026 MATTERS

A convergence year

- **Transformational year: from R&D to commercial-** first revenue-generating products marks Pluri's transition into a revenue-generating biotech.
- **Multiple regulatory inflection points** - anticipated marketing authorizations & regulatory clearances across key programs unlock potential global commercialization and recurring revenue streams.
- **Strategic transactions and partnerships** - each venture engineered with built-in exit routes, positioning every collaboration for a value-realization event.

Our Team

Seasoned leadership with proven track record in life-sciences and capital markets.



Yaky Yanay
CEO & PRESIDENT



Lior Raviv
CHIEF TECHNOLOGY OFFICER



Liat Zalts
CHIEF FINANCIAL OFFICER



Efrat Kaduri
CHIEF BUSINESS OFFICER



Nimrod Bar Zvi
CHIEF COMMERCIAL OFFICER



Ori Shalem
VP OPERATIONS &
MANUFACTURING



Nofar Glaich-Dabach
VP HUMAN RESOURCES

THANK YOU.

FOR FURTHER INFORMATION

investor.relations@pluri-biotech.com · www.pluri-biotech.com

Matam Park, Building 5, Haifa 3508409, Israel · NASDAQ: PLUR · TASE: PLUR.TA